Atypical Antipsychotics in Major Depressive Disorder

  • Laura Orsolini
  • Federica Vellante
  • Alessandro Valchera
  • Michele Fornaro
  • Alessandro Carano
  • Maurizio Pompili
  • Giampaolo Perna
  • Gianluca Serafini
  • Marco Di Nicola
  • Giovanni Martinotti
  • Massimo Di Giannantonio
  • Domenico De Berardis


Depression represents one of the most invalidating and widespread diseases in the Western countries. Depressive episodes could manifest both in unipolar and bipolar mood disorders, hence, not facilitating the choice of the better psychopharmacological treatment. Antidepressants represent the first-line choice in the treatment of a depressive episode within a major depressive disorder (MDD). However, as approximately 10–15% of patients do not adequately respond to a pharmacological therapy, the treatment-resistant depression (TRD) may benefit by atypical antipsychotics as monotherapy or adjunctive therapy. Furthermore, as recently introduced in the Diagnostic and Statistical Manual-5th edition (DSM-5), depressive episodes may occur in association with mixed states, which could justify the prescription of an atypical antipsychotic as add-on therapy. The present chapter aims at reviewing literature and data evaluating the efficacy and effectiveness of prescribing atypical antipsychotics in MDD.


Antipsychotics Atypical antipsychotic Major depressive disorder Depression MDD 


  1. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology. 2009;205(1):119–28.CrossRefGoogle Scholar
  2. Agarwal SM, Rao NP, Venkatasubramanian G, Behere RV, Varambally S, Gangadhar BN. Successful treatment of atypical depression with amisulpride: a case report. Asian J Psychiatr. 2012;5(4):362.CrossRefGoogle Scholar
  3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association; 2013.CrossRefGoogle Scholar
  4. Amore M, Jori MC, AMISERT Investigators. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol. 2001;16(6):317–24.CrossRefGoogle Scholar
  5. Arbaizar B, Dierssen-Sotos T, Gómez-Acebo I, Llorca J. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry. 2009;31(5):478–83.CrossRefGoogle Scholar
  6. Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord. 2013;145(1):62–9.CrossRefGoogle Scholar
  7. Banov MD, Zarate CA Jr, Tohen M, Scialabba D, Wines JD Jr, Kolbrener M, Kim JW, Cole JO. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry. 1994;55:295–300.PubMedGoogle Scholar
  8. Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis. J Clin Psychiatry. 2015;76:728–34.CrossRefGoogle Scholar
  9. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843–53.CrossRefGoogle Scholar
  10. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197–206.CrossRefGoogle Scholar
  11. Björkholm C, Frånberg O, Malmerfelt A, Marcus MM, Konradsson-Geuken Å, Schilström B, Jardemark K, Svensson TH. Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the rat. Int J Neuropsychopharmacol. 2014;18(3): pyu068.CrossRefGoogle Scholar
  12. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, Levinson D, Matschinger H, Mora ME, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.CrossRefGoogle Scholar
  13. Carta MG, Zairo F, Mellino G, et al. An open label follow-up study on amisulpride in the add-on treatment of bipolar I patients. Clin Pract Epidemiol Ment Health. 2006;2:19.CrossRefGoogle Scholar
  14. Carvalho AF, Nunes-Neto PR, Cavalcante JL, Oliveira Lima MC. Amisulpride augmentation after the failure of citalopram for depression: a case report. J Clin Pharm Ther. 2007;32(1):97–9.CrossRefGoogle Scholar
  15. Cassano G, Jori M. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol. 2002;17:27–2.CrossRefGoogle Scholar
  16. Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry. 2011;24(1):10–7.CrossRefGoogle Scholar
  17. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015;69(9):978–97.CrossRefGoogle Scholar
  18. Davis LL, Ota A, Perry P, Tsuneyoshi K, Weiller E, Baker R. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study. Biol Psychiatry. 2015;77(9 Suppl 1):S66.Google Scholar
  19. De Berardis D, Orsolini L, Iasevoli F, Prinzivalli E, de Bartolomeis A, Serroni N, Mazza M, Valchera A, Fornaro M, Vecchiotti R, Carano A, Sepede G, Vellante F, Matarazzo I, Pompili M, Perna G, Conti C, Segura-García C, Martinotti G, Di Giannantonio M. The novel antipsychotic cariprazine (RGH-188): state-of-the-art in the treatment of psychiatric disorders. Curr Pharm Des. 2016;22(33):5144–62.CrossRefGoogle Scholar
  20. Delcourte S, Abrial E, Etiévant A, Rovera R, Arnt J, Didriksen M, Haddjeri N. Asenapine modulates mood-related behaviors and 5-HT(1A/7) receptors-mediated neurotransmission. CNS Neurosci Ther. 2017;23(6):518–25.CrossRefGoogle Scholar
  21. Dimitrakopoulos S, Konstantakopoulos G. Pharmacological agents under research for the maintenance treatment in bipolar disorder. Psychiatriki. 2015;26(3):169–80.PubMedGoogle Scholar
  22. FDA. Advisory Committee Documentation: Seroquel XR® (quetiapine fumarate) for major depressive disorder (MDD) or generalized anxiety disorder (GAD). 2009.Google Scholar
  23. Fornaro M, Stubbs B, De Berardis D, Perna G, Valchera A, Veronese N, Solmi M, Ganança L. Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta-analysis of placebo-controlled clinical trials. Int J Mol Sci. 2016;17(2):241.CrossRefGoogle Scholar
  24. Frakenburg FR. Clozapine and bipolar disorder. J Clin Psychopharmacol. 1993;13:289–90.CrossRefGoogle Scholar
  25. Gigante AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs. 2012;26(5):403–20.CrossRefGoogle Scholar
  26. Greenberg WM, Citrome L. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet. 2017;56(5):493–503.CrossRefGoogle Scholar
  27. Gruenberg AM, Goldstein RD, Pincus HA. Classification of depression: research and diagnostic criteria: DSM-IV and ICD-10. Biology of depression: from novel insights to therapeutic strategies. Weinheim: Wiley; 2008.Google Scholar
  28. Hardoy MC, Carta MG. Strategy to accelerate or augment the antidepressant response and for an early onset of SSRI activity. Adjunctive amisulpride to fluvoxamine in major depressive disorder. Clin Pract Epidemiol Ment Health. 2010;6:1–3.CrossRefGoogle Scholar
  29. Hasnain M, Vieweg WV, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med. 2012;124(4):154–67.CrossRefGoogle Scholar
  30. Heo JY, Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, Pisoni A, Papakostas GI. Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial. J Psychiatr Res. 2015;62:56–61.CrossRefGoogle Scholar
  31. Ionescu DF, Shelton RC, Baer L, Meade KH, Swee MB, Fava M, Papakostas GI. Ziprasidone augmentation for anxious depression. Int Clin Psychopharmacol. 2016;31(6):341–6.CrossRefGoogle Scholar
  32. Jarema M. Atypical antipsychotics in the treatment of mood disorders. Curr Opin Psychiatry. 2007;20(1):23–9.CrossRefGoogle Scholar
  33. Joffe RT, Levitt AJ, Sokolov ST. Augmentation strategies: focus on anxiolytics. J Clin Psychiatry. 1996;57(Suppl 7):25–31.Google Scholar
  34. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res. 2009;43(3):205–14.CrossRefGoogle Scholar
  35. Keller MC, Nesse RM. The evolutionary significance of depressive symptoms: different adverse situations lead to different depressive symptom patterns. J Pers Soc Psychol. 2006;91:316–30.CrossRefGoogle Scholar
  36. Khan A. Current evidence for aripiprazole as augmentation therapy in major depressive disorder. Expert Rev Neurother. 2008;8(10):1435–47.CrossRefGoogle Scholar
  37. Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010;12:CD008121.Google Scholar
  38. Krystal A, Mittoux A, Meisels P, Baker R. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and sleep disturbances: an exploratory study. Biol Psychiatry. 2015;77(9 Suppl 1):S64–5.Google Scholar
  39. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord. 1997;43(2):95–103.CrossRefGoogle Scholar
  40. Li XB, Tang YL, Wang CY, de Leon J. Clozapine for treatment-resistant bipolar disorder: a systematic review. Bipolar Disord. 2015;17(3):235–47.CrossRefGoogle Scholar
  41. Lin CY, Tsai GE, Wang HS, Wu YH, Chiou CC, Wu VY, Lane HY. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study. J Clin Psychiatry. 2014;75(9):e924–31.CrossRefGoogle Scholar
  42. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, Calabrese JR. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:160–8.CrossRefGoogle Scholar
  43. Luan S, Wan H, Wang S, Li H, Zhang B. Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2017;13:609–20.CrossRefGoogle Scholar
  44. Maeda K, Lerdrup L, Suqino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;351(3):686–7.CrossRefGoogle Scholar
  45. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm. 2012;18(5 Suppl B):S1–S20.Google Scholar
  46. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007;147(9):593–602.CrossRefGoogle Scholar
  47. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 2012;12(1):160.CrossRefGoogle Scholar
  48. Marazziti D, Piccinni A, Baroni S, Mungai F, Presta S, Mucci F, Dell'Osso L. Current trends on antipsychotics: focus on asenapine. Curr Med Chem. 2016;23(21):2204–16.CrossRefGoogle Scholar
  49. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156–65.CrossRefGoogle Scholar
  50. McDonagh M, Peterson K, Carson S, Fu R, Thakurta S. Drug class review: atypical antipsychotic drugs: final update 3 report [Internet]. Portland: Oregon Health & Science University; 2010.Google Scholar
  51. McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, Aizley HG, O'Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 1991;52:411–4.PubMedGoogle Scholar
  52. McIntyre RS, Muzina DJ, Adams A, Lourenco MT, Law CW, Soczynska JK, Woldeyohannes HO, Nathanson J, Kennedy SH. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother. 2009;10(18):3061–75.CrossRefGoogle Scholar
  53. McIntyre RS, Weiller E, Zhang P, Weiss C. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post-hoc analysis of two randomized controlled trials. J Affect Disord. 2016;201:116–23.CrossRefGoogle Scholar
  54. Menard F, Fava M, Davidsen CK, Baker RA. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and irritability: an exploratory study. Biol Psychiatry. 2015;77(9 suppl 1):S65.Google Scholar
  55. Montgomery SA. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Int Clin Psychopharmacol. 2002;17(Suppl 4):S9–S15. discussion S16–S17PubMedGoogle Scholar
  56. Monti JM. The effect of second-generation antipsychotic drugs on sleep parameters in patients with unipolar or bipolar disorder. Sleep Med. 2016;23:89–96.CrossRefGoogle Scholar
  57. Muneer A. Pharmacotherapy of acute bipolar depression in adults: an evidence based approach. Korean J Fam Med. 2016;37(3):137–48.CrossRefGoogle Scholar
  58. Nelson JC, Thase ME, Bellocchio EE, Rollin LM, Eudicone JM, McQuade RD, Marcus RN, Berman RM, Baker RA. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol. 2012;27(3):125–33.CrossRefGoogle Scholar
  59. Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo AL, Martinotti G, Mazza M, Perna G, Carano A, De Bartolomeis A, Di Giannantonio M, De Berardis D. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016;15(10):1329–47.CrossRefGoogle Scholar
  60. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs. 2011;25(2):109–27.CrossRefGoogle Scholar
  61. Papakostas GI. Atypical antipsychotic agents for treatment-resistant major depressive disorder. Essent Psychopharmacol. 2005;6(4):209–20.PubMedGoogle Scholar
  62. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65:217–21.CrossRefGoogle Scholar
  63. Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC. Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2015;172(12):1251–8.CrossRefGoogle Scholar
  64. Parikh NB, Robinson DM, Clayton AH. Clinical role of brexpiprazole in depression and schizophrenia. Ther Clin Risk Manag. 2017;13:299–306.CrossRefGoogle Scholar
  65. Pawar GR, Agrawal RP, Phadnis P, Paliwal A, Vyas S, Solanki P. Evaluation of antidepressant like property of amisulpride per se and its comparison with fluoxetine and olanzapine using forced swimming test in albino mice. Acta Pol Pharm. 2009;66(3):327–31.PubMedGoogle Scholar
  66. Politis AM, Papadimitriou GN, Theleritis CG, Psarros C, Soldatos CR. Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1227–30.CrossRefGoogle Scholar
  67. Rexulti® (brexpiprazole) [full prescribing information]. 2015. Available from: Accessed 18 Jan 2016.
  68. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors, focus on newer generation compounds. Life. Science. 2000;68(1):29–39.Google Scholar
  69. Rogóż Z. Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy. Pharmacol Rep. 2013;65(6):1535–44.CrossRefGoogle Scholar
  70. Sanford M. Quetiapine extended release: adjunctive treatment in major depressive disorder. CNS Drugs. 2011;25(9):803–13.CrossRefGoogle Scholar
  71. Schmidt AW, Lebel A, Howard HR Jr, Zom SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197–201.CrossRefGoogle Scholar
  72. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008;117(4):253–9.CrossRefGoogle Scholar
  73. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord. 1998;48(1):47–56.CrossRefGoogle Scholar
  74. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1–2):83–91.CrossRefGoogle Scholar
  75. Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016;21(1):1–6.CrossRefGoogle Scholar
  76. Stahl SM, Morrissette DA, Faedda G, Fava M, Goldberg JF, Keck PE, Lee Y, Malhi G, Marangoni C, McElroy SL, Ostacher M, Rosenblat JD, Solé E, Suppes T, Takeshim M, Thase ME, Vieta E, Young A, Zimmerman M, McIntyre RS. Guidelines for the recognition and management of mixed depression. CNS Spectr. 2017;22(2):203–19.CrossRefGoogle Scholar
  77. Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry. 2011;11:101.CrossRefGoogle Scholar
  78. Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012;13(13):1911–22.CrossRefGoogle Scholar
  79. Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999;368(2–3):277–83.CrossRefGoogle Scholar
  80. Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012;29(7):574–86.CrossRefGoogle Scholar
  81. Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015a;76(9):1224–31.CrossRefGoogle Scholar
  82. Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015b;76(9):1232–40.CrossRefGoogle Scholar
  83. Torta R, Berra C, Binaschi L, Borio R. Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies. Support Care Cancer. 2007;15(5):539–46.CrossRefGoogle Scholar
  84. Ward MP, Irazoqui PP. Evolving refractory major depressive disorder diagnostic and treatment paradigms: toward closed-loop therapeutics. Front Neuroeng. 2010;3:7.PubMedPubMedCentralGoogle Scholar
  85. Weber J, Lyseng-Williamson KA, Scott LJ. Aripiprazole: in major depressive disorder. CNS Drugs. 2008;22(10):807–13.CrossRefGoogle Scholar
  86. Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2012;27(1):27–39.CrossRefGoogle Scholar
  87. Yan JX. A double-blind clinical trial of add-on clozapine in the treatment of treatment-resistant depression. Clin J Psychol Med. 2001;11:170–1.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Laura Orsolini
    • 1
    • 2
  • Federica Vellante
    • 2
    • 3
  • Alessandro Valchera
    • 2
    • 4
  • Michele Fornaro
    • 5
  • Alessandro Carano
    • 6
  • Maurizio Pompili
    • 7
  • Giampaolo Perna
    • 8
    • 9
    • 10
  • Gianluca Serafini
    • 11
  • Marco Di Nicola
    • 12
  • Giovanni Martinotti
    • 3
  • Massimo Di Giannantonio
    • 3
  • Domenico De Berardis
    • 3
    • 12
    • 13
  1. 1.Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical SciencesUniversity of HatfieldHatfieldUK
  2. 2.Polyedra Research GroupTeramoItaly
  3. 3.Department of Neurosciences and ImagingUniversity “G. d’Annunzio”ChietiItaly
  4. 4.Villa S. Giuseppe, Hospital Hermanas HospitalariasAscoli PicenoItaly
  5. 5.Laboratory of Molecular Psychiatry and Psychopharmacotherapeutics, Unit of Psychiatry, Department of NeuroscienceUniversity School of Medicine “Federico II”NaplesItaly
  6. 6.Department of Mental Health, Psychiatric Service of Diagnosis and TreatmentHospital “Madonna Del Soccorso”, NHSSan Benedetto del TrontoItaly
  7. 7.Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea HospitalSapienza University of RomeRomeItaly
  8. 8.Department of Clinical NeurosciencesVilla San Benedetto Menni, Hermanas Hospitalarias, FoRiPsiAlbese con CassanoItaly
  9. 9.Department of Psychiatry and NeuropsychologyUniversity of MaastrichtMaastrichtThe Netherlands
  10. 10.Department of Psychiatry and Behavioral Sciences, Leonard Miller School of MedicineUniversity of MiamiMiamiUSA
  11. 11.Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of PsychiatryUniversity of Genoa, IRCCS San MartinoGenoaItaly
  12. 12.Institute of Psychiatry and PsychologyFondazione Policlinico Universitario “A. Gemelli”, Università Cattolica del Sacro CuoreRomeItaly
  13. 13.National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and TreatmentHospital “G. Mazzini”TeramoItaly

Personalised recommendations